logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

Celularity Inc NK Cell Therapy CYNK-001 Receives US FDA Fast Track Designation for AML Treatment

Celularity Inc Celularity Inc. ( CELU ) announced the U.S. Food and Drug Administration ( FDA ) has granted Fast Track Designation for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer ( NK ) cell therapy, CYNK-001...

Read More

December 28, 2021

0

TG Therapeutics: Promising Investigational Monoclonal Antibody Ublituximab for Relapsing Form of M.S.

TG Therapeutics Results Published in NEJM TG Therapeutics ( TGTX ) results from the ULTIMATE I & II Phase 3 trials evaluating the firm’s investigational monoclonal antibody product ublituximab in patients with relapsing forms of multiple sclerosis ( RMS )...

Read More

August 31, 2022

0

bluebird bio: The Appealing Decision to Separate its Severe Genetic Disease and Oncology Businesses into Independent Publicly-Traded Firms

bluebird bio Decision to Separate its Businesses bluebird bio ( BLUE )  will retain focus on its severe genetic disease ( SGD ) and will launch its oncology business ( Oncology Newco ) as a new entity. The Board of Directors...

Read More

January 14, 2021

0

Compugen: Why the Great Expectations from this Firm

The Compugen Story For those who are still asking about the value of Compugen’s ( CGEN ) discoveries our answer is that the best story written about this firm is its own autobiography.   We believe Compugen's accomplishments are extremely...

Read More

January 22, 2021

0

Why Intellia Therapeutics Acquisition of Rewrite Therapeutics Is Important

Intellia Therapeutics Acquires Rewrite Therapeutics The acquisition is, indeed good news. By acquiring Rewrite Therapeutics , Intellia Therapeutics ( NTLA ) has inherited a versatile DNA writing platform which enables a range of innovative genome editing strategies. The acquisition is...

Read More

February 7, 2022

0

An Important Milestone for Regenxbio Treatment of Wet AMD

Regenxbio Good News for wet AMD On January 10, 2022,   Regenxbio Inc. ( RGNX ) announced the initiation of ASCENT, the second of two Phase 3 pivotal trials to evaluate the efficacy and safety of subretinal delivery of RGX-314 in...

Read More

February 8, 2022

0

Who Forgot About Enanta Pharmaceuticals?

Enanta Pharmaceuticals Expectations Expecting Dosing in a First-in-Human Study of EDP-235, an Oral 3CL Protease Inhibitor Specifically Designed for the Treatment of COVID-19 The Firm Completed Enrollment in RSVP, a Phase 2b Conducted Trial of EDP-938 in Adults With Community-Acquired...

Read More

February 11, 2022

0

Karyopharm Therapeutics Getting a Boost in the Midst of a Chaotic Market

We do not dare invest in the stock market at a time when almost all the stocks, both large and small, are yo-yoing for unknown reasons. The positive criteria has all but vanished, leaving behind it unparalleled inflation that is...

Read More

February 14, 2022

0

Merck Has Interesting News and Impressive Results

Merck Discontinues Development of COVID-19 Vaccine Candidates Merck ( MRK )  known as MSD outside the United States and Canada announced yesterday that the company is discontinuing the development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591. This decision follows...

Read More

January 26, 2021

0

Aurinia Pharmaceuticals: FDA Approved LUPKYNIS for Active Lupus Nephritis in Adults  

Aurinia Pharmaceuticals LUPKYNIS Approved for LN in Adults Aurinia Pharmaceuticals ( AUPH ) has been granted a U.S. FDA approval of its product LUPKYNIS™ (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus...

Read More

January 27, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 36
  • 37
  • 38
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy